The global antibiotics market size accounted for USD 47.36 billion in 2024, grew to USD 49.82 billion in 2025 and is predicted to surpass around USD 78.63 billion by 2034, representing a healthy CAGR of 5.20% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Antibiotics Market, by Drug Class, 2024-2034
7.1.1. Cephalosporin
7.1.1.1. Market Revenue and Forecast (2021-2034)
7.1.2. Penicillin
7.1.2.1. Market Revenue and Forecast (2021-2034)
7.1.3. Fluoroquinolone
7.1.3.1. Market Revenue and Forecast (2021-2034)
7.1.4. Macrolide
7.1.4.1. Market Revenue and Forecast (2021-2034)
7.1.5. Carbapenem
7.1.5.1. Market Revenue and Forecast (2021-2034)
7.1.6. Aminoglycoside
7.1.6.1. Market Revenue and Forecast (2021-2034)
7.1.7. Sulfonamide
7.1.7.1. Market Revenue and Forecast (2021-2034)
7.1.8. 7-ACA
7.1.8.1. Market Revenue and Forecast (2021-2034)
7.1.9. 7-Others
7.1.9.1. Market Revenue and Forecast (2021-2034)
8.1. Antibiotics Market, by Application, 2024-2034
8.1.1. Skin infections
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Urinary tract infection
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Ear infection
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Septicemia
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Respiratory infections
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Gastrointestinal infections
8.1.6.1. Market Revenue and Forecast (2021-2034)
9.1. Antibiotics Market, by Action Mechanism, 2024-2034
9.1.1. Cell Wall Synthesis Inhibitors
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Protein Synthesis Inhibitors
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. DNA Synthesis Inhibitors
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. RNA Synthesis Inhibitors
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2021-2034)
10.1. Antibiotics Market, by Drug Origin, 2024-2034
10.1.1. Natural
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Synthetic
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. Antibiotics Market, by Spectrum Of Activity, 2024-2034
11.1.1. Broad-spectrum Antibiotic
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Narrow-spectrum Antibiotic
11.1.2.1. Market Revenue and Forecast (2021-2034)
12.1. Antibiotics Market, by Route of Administration, 2024-2034
12.1.1. Oral
12.1.1.1. Market Revenue and Forecast (2021-2034)
12.1.2. Parenteral
12.1.2.1. Market Revenue and Forecast (2021-2034)
13.1. Antibiotics Market, by Distribution Channel, 2024-2034
13.1.1. Retail pharmacies
13.1.1.1. Market Revenue and Forecast (2021-2034)
13.1.2. Online pharmacies
13.1.2.1. Market Revenue and Forecast (2021-2034)
13.1.3. Hospitals
13.1.3.1. Market Revenue and Forecast (2021-2034)
13.1.4. Clinics
13.1.4.1. Market Revenue and Forecast (2021-2034)
14.1. North America
14.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.1.2. Market Revenue and Forecast, by Application (2021-2034)
14.1.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.1.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.1.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.1.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.1.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.1.8.2. Market Revenue and Forecast, by Application (2021-2034)
14.1.8.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.1.8.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.1.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.1.8.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.1.8.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.1.9.2. Market Revenue and Forecast, by Application (2021-2034)
14.1.9.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.1.9.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.1.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.1.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.1.9.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.2. Europe
14.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.2.2. Market Revenue and Forecast, by Application (2021-2034)
14.2.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.2.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.2.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.2.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.2.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.2.8.2. Market Revenue and Forecast, by Application (2021-2034)
14.2.8.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.2.8.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.2.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.2.8.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.2.8.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.2.9.2. Market Revenue and Forecast, by Application (2021-2034)
14.2.9.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.2.9.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.2.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.2.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.2.9.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.2.10.2. Market Revenue and Forecast, by Application (2021-2034)
14.2.10.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.2.10.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.2.10.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.2.10.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.2.10.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.2.11.2. Market Revenue and Forecast, by Application (2021-2034)
14.2.11.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.2.11.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.2.11.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.2.11.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.2.11.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.3.2. Market Revenue and Forecast, by Application (2021-2034)
14.3.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.3.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.3.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.3.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.3.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.3.8.2. Market Revenue and Forecast, by Application (2021-2034)
14.3.8.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.3.8.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.3.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.3.8.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.3.8.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.3.9.2. Market Revenue and Forecast, by Application (2021-2034)
14.3.9.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.3.9.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.3.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.3.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.3.9.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.3.10.2. Market Revenue and Forecast, by Application (2021-2034)
14.3.10.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.3.10.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.3.10.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.3.10.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.3.10.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.3.11.2. Market Revenue and Forecast, by Application (2021-2034)
14.3.11.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.3.11.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.3.11.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.3.11.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.3.11.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.4.2. Market Revenue and Forecast, by Application (2021-2034)
14.4.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.4.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.4.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.4.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.4.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.4.8.2. Market Revenue and Forecast, by Application (2021-2034)
14.4.8.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.4.8.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.4.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.4.8.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.4.8.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.4.9.2. Market Revenue and Forecast, by Application (2021-2034)
14.4.9.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.4.9.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.4.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.4.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.4.9.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.4.10.2. Market Revenue and Forecast, by Application (2021-2034)
14.4.10.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.4.10.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.4.10.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.4.10.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.4.10.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.4.11.2. Market Revenue and Forecast, by Application (2021-2034)
14.4.11.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.4.11.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.4.11.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.4.11.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.4.11.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.5.2. Market Revenue and Forecast, by Application (2021-2034)
14.5.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.5.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.5.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.5.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.5.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.5.8.2. Market Revenue and Forecast, by Application (2021-2034)
14.5.8.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.5.8.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.5.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.5.8.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.5.8.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)
14.5.9.2. Market Revenue and Forecast, by Application (2021-2034)
14.5.9.3. Market Revenue and Forecast, by Action Mechanism (2021-2034)
14.5.9.4. Market Revenue and Forecast, by Drug Origin (2021-2034)
14.5.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2021-2034)
14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.5.9.7. Market Revenue and Forecast, by Route of Administration (2021-2034)
15.1. Abbott Laboratories (US)
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Pfizer Inc. (US)
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Johnson & Johnson Services
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. GlaxoSmithKline PLC (UK)
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Sanofi (France)
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Bristol-Myers Squibb Company (US)
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Eli Lilly and Company (US)
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Novartis AG (Switzerland)
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Bayer AG (Germany)
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Astellas Pharma Inc. (Japan)
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client